172 related articles for article (PubMed ID: 9106433)
1. Insights into mechanisms of antiarrhythmic drug action from experimental models of atrial fibrillation.
Nattel S; Bourne G; Talajic M
J Cardiovasc Electrophysiol; 1997 Apr; 8(4):469-80. PubMed ID: 9106433
[TBL] [Abstract][Full Text] [Related]
2. Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use-dependent effects on refractoriness.
Wang J; Bourne GW; Wang Z; Villemaire C; Talajic M; Nattel S
Circulation; 1993 Sep; 88(3):1030-44. PubMed ID: 8353865
[TBL] [Abstract][Full Text] [Related]
3. Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide.
Wang J; Feng J; Nattel S
Circulation; 1994 Oct; 90(4):2032-40. PubMed ID: 7923691
[TBL] [Abstract][Full Text] [Related]
4. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
[TBL] [Abstract][Full Text] [Related]
5. Electrophysiological properties of the fibrillating atrium: implications for therapy.
Tse HF; Lau CP
Clin Exp Pharmacol Physiol; 1998 May; 25(5):293-302. PubMed ID: 9612655
[TBL] [Abstract][Full Text] [Related]
6. Electrophysiological effects of flecainide and sotalol in the human atrium during persistent atrial fibrillation.
Kirchhof P; Engelen M; Franz MR; Ribbing M; Wasmer K; Breithardt G; Haverkamp W; Eckardt L
Basic Res Cardiol; 2005 Mar; 100(2):112-21. PubMed ID: 15696400
[TBL] [Abstract][Full Text] [Related]
7. Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs.
Duytschaever M; Blaauw Y; Allessie M
Cardiovasc Res; 2005 Jul; 67(1):69-76. PubMed ID: 15949471
[TBL] [Abstract][Full Text] [Related]
8. Antiarrhythmic agents for atrial fibrillation: focus on prolonging atrial repolarization.
Singh BN; Mody FV; Lopez B; Sarma JS
Am J Cardiol; 1999 Nov; 84(9A):161R-173R. PubMed ID: 10568677
[TBL] [Abstract][Full Text] [Related]
9. The class III antiarrhythmic drugs dofetilide and sotalol prevent AF induction by atrial premature complexes at doses that fail to terminate AF.
Derakhchan K; Villemaire C; Talajic M; Nattel S
Cardiovasc Res; 2001 Apr; 50(1):75-84. PubMed ID: 11282080
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological approaches in the treatment of atrial fibrillation.
Tamargo J; Caballero R; Delpón E
Curr Med Chem; 2004 Jan; 11(1):13-28. PubMed ID: 14754423
[TBL] [Abstract][Full Text] [Related]
11. [Problems with anti-arrhythmia therapy in atrial fibrillation].
Breithardt G; Kottkamp H; Haverkamp W; Hindricks G; Fetsch T; Borggrefe M
Z Kardiol; 1994; 83 Suppl 5():63-9. PubMed ID: 7846947
[TBL] [Abstract][Full Text] [Related]
12. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management.
Gillis AM; Verma A; Talajic M; Nattel S; Dorian P;
Can J Cardiol; 2011; 27(1):47-59. PubMed ID: 21329862
[TBL] [Abstract][Full Text] [Related]
13. Is oral sotalol effective in converting atrial fibrillation to sinus rhythm?
Ferreira E; Sunderji R; Gin K
Pharmacotherapy; 1997; 17(6):1233-7. PubMed ID: 9399605
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of termination of atrial fibrillation by Class I antiarrhythmic drugs: evidence from clinical, experimental, and mathematical modeling studies.
Nattel S; Kneller J; Zou R; Leon LJ
J Cardiovasc Electrophysiol; 2003 Oct; 14(10 Suppl):S133-9. PubMed ID: 14760915
[TBL] [Abstract][Full Text] [Related]
15. [Epidemiology and therapy of atrial fibrillation].
Capucci A; Aschieri D; Villani GQ
Ann Ital Med Int; 1996 Oct; 11 Suppl 2():5S-10S. PubMed ID: 9004821
[TBL] [Abstract][Full Text] [Related]
16. Targeted pharmacological reversal of electrical remodeling after cardioversion--rationale and design of the Flecainide Short-Long (Flec-SL) trial.
Kirchhof P; Fetsch T; Hanrath P; Meinertz T; Steinbeck G; Lehmacher W; Breithardt G
Am Heart J; 2005 Nov; 150(5):899. PubMed ID: 16290956
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of flecainide's antiarrhythmic action in experimental atrial fibrillation.
Wang Z; Pagé P; Nattel S
Circ Res; 1992 Aug; 71(2):271-87. PubMed ID: 1628386
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic cardioversion of chronic atrial fibrillation in the goat by class IA, IC, and III drugs: a comparison between hydroquinidine, cibenzoline, flecainide, and d-sotalol.
Wijffels MC; Dorland R; Allessie MA
J Cardiovasc Electrophysiol; 1999 Feb; 10(2):178-93. PubMed ID: 10090222
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic management of supraventricular tachycardias in children. Part 2: Atrial flutter, atrial fibrillation, and junctional and atrial ectopic tachycardia.
Luedtke SA; Kuhn RJ; McCaffrey FM
Ann Pharmacother; 1997 Nov; 31(11):1347-59. PubMed ID: 9391691
[TBL] [Abstract][Full Text] [Related]
20. Limitations to antiarrhythmic drug use in patients with atrial fibrillation.
Humphries KH; Kerr CR; Steinbuch M; Dorian P;
CMAJ; 2004 Sep; 171(7):741-5. PubMed ID: 15451836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
